Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

Open access

Abstract

Background In a phase 2 trial, lenvatinib, an inhibitor of VEGF receptors 1-3, FGF receptors 1-4, PDGF receptor α, RET, and KIT, showed activity in hepatocellular carcinoma. We aimed to compare overall survival in patients treated with lenvatinib versus sorafenib as a first-line treatment for unresectable hepatocellular carcinoma.Methods This was an open-label, phase 3, multicentre, non-inferiority trial that recruited patients with unresectable hepatocellular carcinoma, who had not received treatment for advanced disease, at 154 sites in 20 countries throughout the Asia-Pacific, European, and North American regions. Patients were randomly assigned (1:1) via an interactive voice-web response system-with region; macroscopic portal vein invasion, extrahepatic spread, or both; Eastern Cooperative Oncology Group performance status; and bodyweight as stratification factors-to receive oral lenvatinib (12 mg/day for bodyweight ≥60 kg or 8 mg/day for bodyweight <60 kg) or sorafenib 400 mg twice-daily in 28-day cycles. The primary endpoint was overall survival, measured from the date of randomisation until the date of death from any cause. The efficacy analysis followed the intention-to-treat principle, and only patients who received treatment were included in the safety analysis. The non-inferiority margin was set at 1·08. The trial is registered with ClinicalTrials.gov, number NCT01761266.Findings Between March 1, 2013 and July 30, 2015, 1492 patients were recruited. 954 eligible patients were randomly assigned to lenvatinib (n=478) or sorafenib (n=476). Median survival time for lenvatinib of 13·6 months (95% CI 12·1-14·9) was non-inferior to sorafenib (12·3 months, 10·4-13·9; hazard ratio 0·92, 95% CI 0·79-1·06), meeting criteria for non-inferiority. The most common any-grade adverse events were hypertension (201 [42%]), diarrhoea (184 [39%]), decreased appetite (162 [34%]), and decreased weight (147 [31%]) for lenvatinib, and palmar-plantar erythrodysaesthesia (249 [52%]), diarrhoea (220 [46%]), hypertension (144 [30%]), and decreased appetite (127 [27%]) for sorafenib.Interpretation Lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma. The safety and tolerability profiles of lenvatinib were consistent with those previously observed.Funding Eisai Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)30207-1

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 5,497

Metadata

Authors
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., Blanc, J. F., Vogel, A., Komov, D., Evans, T. R. J., Lopez, C., Dutcus, C., Guo, M., Saito, K., Kraljevic, S., Tamai, T., Ren, M., & Cheng, A.-L.
Affiliations
  • Kindai University Hospital (JP)
  • University of California, Los Angeles (US)
  • 81th Hospital of PLA (CN)
  • Yonsei University (KR)
  • Toranomon Hospital (JP)
  • University of Bologna (IT)
  • California Pacific Medical Center (US)
  • National Cancer Center (KR)
  • Xijing Hospital (CN)
  • Gdańsk Medical University (PL)
  • Medizinische Hochschule Hannover (DE)
  • Beatson West of Scotland Cancer Centre (GB)
  • Eisai (United States) (US)
  • Eisai (United Kingdom) (GB)
  • National Taiwan University Hospital (TW)
Corresponding author
Kudo, Masatoshi
Venue
The Lancet
Publisher
Elsevier BV
Published
2018-03
Volume
391
Issue
10126
Pages
1163-1173
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2787358630
Cited by
5,497
References
32
Citations by year
2026: 433 · 2025: 672 · 2024: 770 · 2023: 829 · 2022: 791 · 2021: 817 · 2020: 646 · 2019: 391 · 2018: 135
FWCI
309.45
Type
journal article
Language
en
Open access
Licence
  • cc-by-sa
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
Funders
Eisai Incorporated
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords
lenvatinib, sorafenib, hepatocellular carcinoma, unresectable liver cancer, first-line therapy, overall survival, non-inferiority, tyrosine kinase inhibitors, VEGF receptor inhibition, RET inhibition, KIT inhibition, PDGF receptor alpha, hypertension, diarrhea, adverse events
MeSH terms
Sorafenib, Aged, Antineoplastic Agents, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Niacinamide, Phenylurea Compounds, Quinolines, Survival Rate, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)30207-1
The paper
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., Blanc, J. F., Vogel, A., Komov, D., Evans, T. R. J., Lopez, C., Dutcus, C., Guo, M., Saito, K., Kraljevic, S., . . . Cheng, A.-L. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)30207-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.